9/14/2026
Psyence BioMed launches US ibogaine subsidiary
New Texas-based entity to spearhead ibogaine research and development in the US.
Topic archive
psylabs
7 stories
9/14/2026
Psyence BioMed expands U.S. ibogaine research with Texas unit
New subsidiary aims to centralize ibogaine supply and regulatory efforts in the U.S.
9/14/2026
Psyence BioMed forms Texas entity for U.S. ibogaine research
Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Psyence BioMed backs Trump ibogaine initiative
Company aligns with U.S. efforts to advance ibogaine research.
8/8/2026
Psyence BioMed focuses on psilocybin and ibogaine supply
The biotech firm aims for vertical integration in psychedelic therapeutics.
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.